Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STRO-004 · 1 trial · 9 indications
Best response of Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)
The proportion of participants with best response of CR, PR or Stable Disease (SD) per RECIST V1.1
Time from first occurrence of objective response to the time of Progressive Disease (PD) according to RECIST v1.1 or death from any cause, whichever comes first
Time from first dose to the first occurrence of PD according to RECIST v1.1 or death from any cause, whichever comes first
Percentage of participants alive 12 months after first dose of study treatment
| Arm | Type | Description |
|---|---|---|
| Part 1A STRO-004 Monotherapy | EXPERIMENTAL | - |
| Part 1B STRO-004 Monotherapy | EXPERIMENTAL | - |
| Part 1C STRO-004 in Combination with Pembrolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| STRO-004 | DRUG | IV Infusion |
| Pembrolizumab | DRUG | IV Infusion |
Inclusion Criteria: * Histologically or cytologically documented metastatic or locally advanced solid tumors including: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Esophageal/Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Cervical Cancer, Endometrial Can...
STRO-004 is an investigational small molecule being developed for the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). It is also being studied in other advanced solid tumors including non-small cell lung cancer, esophageal, gastric, colorectal, pancreatic, cervical, endometrial, and urothelial cancers. The drug is currently in Phase 1 clinical development.
STRO-004 targets Tissue Factor, a protein involved in blood clotting and cancer progression. By binding to this target, the drug aims to interfere with tumor growth and spread. This mechanism is being evaluated in a Phase 1 clinical trial for patients with refractory or recurrent metastatic cancers.
STRO-004 is being developed by Sutro Biopharma, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol STRO. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced solid tumors.
STRO-004 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is recruiting patients to assess the drug's safety, tolerability, and preliminary efficacy in adults with refractory or recurrent metastatic cancer.
STRO-004 is being studied in a Phase 1 clinical trial registered as NCT07227168, titled 'A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer.' This recruiting trial is enrolling approximately 200 participants in the United States, including patients with Head and Neck Squamous Cell Carcinoma and other advanced solid tumors.
No, STRO-004 is not the same as Tissue Factor. STRO-004 is the investigational drug, while Tissue Factor is the molecular target that the drug binds to. The drug is designed to interact with this protein to potentially treat cancers such as Head and Neck Squamous Cell Carcinoma.